Ivermectin and Cancer Clinical Trials: What the Research Shows
Written by: North Editorial Staff, clinically reviewed by Laura Morrissey, RN, BSN · Last reviewed: February 2026 · Next review due: February 2027
Key Takeaways
Ivermectin is an FDA-approved antiparasitic drug. It is not approved, recommended, or proven as a cancer treatment.
Laboratory studies have shown that ivermectin can inhibit cancer cell growth in controlled settings. These preclinical results are scientifically interesting but have not been confirmed in human clinical trials.
As of early 2026, only a small number of early-phase clinical trials are studying ivermectin in cancer — primarily a Phase 1/II trial for metastatic triple-negative breast cancer. No Phase 3 trial data exists.
The gap between lab results and proven human treatment is a normal part of drug development that applies to all potential new therapies, not just ivermectin.
If you're interested in new cancer treatments, the safest path is through a clinical trial with proper medical oversight, IRB approval, and safety monitoring.
What Is Ivermectin?
Ivermectin is a medication originally developed in the late 1970s by Japanese microbiologist Satoshi Ōmura and Irish parasitologist William C. Campbell. Their work earned the 2015 Nobel Prize in Physiology or Medicine for discovering a drug that transformed the treatment of parasitic diseases worldwide.
The FDA has approved ivermectin for several specific uses. As an oral medication, it is approved to treat intestinal strongyloidiasis (a roundworm infection) and onchocerciasis (river blindness). In topical form, it is approved for the treatment of head lice and rosacea. The drug has been used safely for decades in these applications and has been administered to hundreds of millions of people globally through public health programs targeting parasitic diseases.
Ivermectin is not approved by the FDA for the treatment of cancer. It is also not recommended for cancer treatment by any major oncology organization or clinical guideline body, including the National Comprehensive Cancer Network (NCCN) or the American Society of Clinical Oncology (ASCO).
Where the Cancer Claims Come From
Interest in ivermectin as a potential cancer treatment stems from laboratory research — studies conducted on cancer cells in petri dishes (called in vitro studies) and in animal models. These preclinical studies have generated genuine scientific interest, and understanding what they found helps explain why the topic has attracted so much attention.
According to a 2021 review published in Pharmacological Research, laboratory studies have shown that ivermectin can inhibit the growth of cancer cells, trigger programmed cell death (apoptosis), and interfere with signaling pathways that cancer cells use to grow and spread. These effects have been observed across multiple cancer types in lab settings, including breast, colon, ovarian, lung, and blood cancers.
More recently, a 2025 review in Current Oncology Reports confirmed that preclinical studies continue to demonstrate anticancer effects — including inhibition of cell proliferation, induction of apoptosis, and modulation of pathways such as Wnt/β-catenin and Akt/mTOR. Some lab research has also suggested that ivermectin may enhance the activity of immunotherapy drugs and help overcome resistance to certain chemotherapy agents.
These findings are scientifically interesting. But there is a critical distinction that often gets lost in media coverage and social media discussions: showing that a substance can kill cancer cells in a laboratory is not the same as showing it can safely and effectively treat cancer in a human being. Many substances — including common household items like bleach and baking soda — can destroy cancer cells in a dish. That does not make them cancer treatments.
The leap from laboratory promise to proven human therapy requires years of rigorous testing through clinical trials — and that is where ivermectin's story becomes much more limited.
What the Clinical Research Actually Shows
As of early 2026, human clinical evidence for ivermectin as a cancer treatment is extremely limited. According to a 2025 analysis presented at the European Society for Medical Oncology (ESMO) annual meeting, researchers identified approximately 50 preclinical studies examining ivermectin and cancer — but found no published clinical studies demonstrating effectiveness in human cancer patients.
What's Currently Being Tested
A search of ClinicalTrials.gov reveals a very small number of trials investigating ivermectin in cancer:
NCT05318469 is a Phase 1/II clinical trial at Cedars-Sinai Medical Center evaluating ivermectin in combination with balstilimab (an immunotherapy drug) for patients with metastatic triple-negative breast cancer. This trial is testing safety, dosing, and early signals of effectiveness. It is expected to report results around 2026. This is the most prominent active trial studying ivermectin in an oncology context.
NCT02366884 is a Phase 2 trial examining an approach called "atavistic chemotherapy" that includes ivermectin alongside other repurposed drugs for patients with advanced cancers. This trial uses a different theoretical framework and is much smaller in scope.
These are early-phase studies. They are designed primarily to assess safety and gather preliminary data — not to prove that ivermectin works as a cancer treatment. No Phase 3 trial — the large-scale, randomized study required to establish whether a treatment is effective enough to become standard care — has been conducted or is currently registered for ivermectin in any cancer type.
What the Evidence Does Not Support
No major oncology guideline recommends ivermectin for cancer treatment. No FDA approval has been granted or sought for ivermectin as an anti-cancer drug. According to the 2025 review in Current Oncology Reports, the authors concluded that despite promising preclinical data, the absence of large-scale human clinical evidence limits ivermectin's utility in cancer treatment. The review also warned that self-medication with ivermectin driven by social media claims can lead to toxicity in cancer patients.
This does not mean ivermectin will never prove useful in cancer treatment. It means the evidence is not yet there — and taking ivermectin for cancer outside of a supervised clinical trial carries risks without proven benefits.
Why Lab Results Don't Always Translate to Treatment
The gap between laboratory findings and effective human treatment is one of the most important concepts in medicine and it applies to every potential new drug, not just ivermectin.
How Drug Development Actually Works
The path from scientific discovery to approved treatment follows a well-established pipeline. It begins with laboratory research, where scientists test compounds against cancer cells in controlled environments. Promising compounds then advance to animal studies, where researchers evaluate safety and effectiveness in living organisms. Only after clearing these hurdles can a treatment enter human clinical trials — a process that unfolds across multiple phases.
Phase 1 trials test safety and dosing in a small group of patients (typically 20 to 100). Phase 2 trials evaluate whether the treatment shows signs of effectiveness in a larger group (100 to 500). Phase 3 trials compare the new treatment to standard care in large, randomized studies (often 1,000 or more participants). Only after successfully completing Phase 3 can a drug be submitted for FDA approval.
According to the FDA, the entire process from laboratory discovery to approval takes an average of 8 to 15 years. And the vast majority of compounds that show promise in the lab never make it through. Estimates suggest that fewer than 10% of drugs entering Phase 1 trials ultimately receive FDA approval.
This Isn't Unique to Ivermectin
Many well-known substances have shown the ability to kill cancer cells in laboratory settings but have failed to produce meaningful results in human clinical trials. This is a normal part of the scientific process, not evidence of suppression or conspiracy. The reasons compounds fail in humans include the drug not reaching tumors at effective concentrations in the body, side effects that outweigh benefits at the doses required, differences between how cancer cells behave in a dish versus inside a living person, and the human immune system and metabolism interacting with the drug in unexpected ways.
The protocol for clinical trials exists specifically to answer these questions in a controlled, safe environment — protecting patients while generating the evidence needed to determine whether a treatment truly works.
How to Find Legitimate Cancer Clinical Trials
If you're interested in exploring new or emerging cancer treatments — whether ivermectin-related or otherwise — the safest and most productive path is through a properly conducted clinical trial with full medical oversight.
What Makes a Trial Legitimate
Every legitimate clinical trial in the United States must be approved by an Institutional Review Board (IRB), which is an independent committee that reviews the study to protect participants' rights and safety. Participants go through informed consent, ensuring they understand the study's purpose, procedures, risks, and their right to withdraw at any time. An independent Data Safety Monitoring Board monitors safety data throughout the trial and can stop it if concerns arise.
These protections exist because experimental treatments are, by definition, not yet proven. Clinical trials provide the structure to test new ideas while prioritizing your safety — something that self-medicating with unproven treatments cannot offer.
How to Search for Trials
ClinicalTrials.gov is the most comprehensive public database of clinical trials worldwide. You can search by cancer type, treatment being studied, trial phase, and location. If you're specifically interested in ivermectin trials, you can search the database directly for "ivermectin" and "cancer" to see what studies are active.
Talk to your oncologist. Your doctor can help you evaluate whether any available trial — including those studying drug repurposing approaches — is appropriate for your specific cancer type, stage, and treatment history. If your oncologist isn't aware of a trial you've found, they can review the protocol and help you make an informed decision.
Use a trial matching service. Services like North match your specific diagnosis details to thousands of trials and can help you find options you might not discover on your own.
A Note on Self-Medication
Taking ivermectin — or any drug — for cancer without medical supervision is not a substitute for participating in a clinical trial. According to the FDA, using ivermectin for unapproved purposes can result in serious adverse events, including liver damage, and may interact with cancer treatments you're already receiving. If you're interested in ivermectin's potential, the responsible path is to discuss it with your oncologist and explore whether a clinical trial is available.
Frequently Asked Questions
Is ivermectin a proven cancer treatment?
No. While laboratory studies have shown that ivermectin can affect cancer cells in controlled settings, no large-scale clinical trial has demonstrated that it is safe and effective as a cancer treatment in humans. As of early 2026, only a few early-phase trials are investigating ivermectin in cancer, and no results have established it as a viable therapy.
Are there any clinical trials studying ivermectin for cancer?
Yes, a small number. The most notable is a Phase 1/II trial at Cedars-Sinai Medical Center (NCT05318469) testing ivermectin in combination with immunotherapy for metastatic triple-negative breast cancer. You can search ClinicalTrials.gov for current studies. However, these are early-phase trials designed to assess safety and preliminary signals — not to confirm effectiveness.
Why do some people believe ivermectin cures cancer?
The belief is primarily driven by preclinical laboratory studies showing that ivermectin can kill cancer cells in petri dishes and slow tumor growth in animal models. These findings have been amplified by social media and online communities. While the lab research is real, the critical gap is that laboratory results frequently do not translate to effective treatments in humans. This is true for many compounds, not just ivermectin.
Is it safe to take ivermectin on my own for cancer?
No. Taking ivermectin outside of a supervised clinical trial for cancer is not recommended by the FDA, the NCI, or any major oncology organization. Self-medicating with ivermectin can cause serious side effects, may interact with your current cancer treatment, and delays access to proven therapies. If you're interested in ivermectin's potential, talk to your oncologist about whether a clinical trial is appropriate.
What should I do if I want to try alternative cancer treatments?
Talk to your oncologist openly about any treatments you're interested in, including alternative or repurposed drugs. Many cancer centers now have integrative oncology programs that can evaluate complementary approaches alongside your standard care. If a treatment is being studied in a clinical trial, that is the safest and most responsible way to access it — with proper medical supervision, safety monitoring, and informed consent.
Interested in exploring new cancer treatments? Find clinical trials with proper medical oversight through North's trial finder.
References
U.S. Food and Drug Administration. "FAQ: COVID-19 and Ivermectin Intended for Animals." https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-ivermectin-intended-animals
Fang Q, et al. "Ivermectin, a potential anticancer drug derived from an antiparasitic drug." Pharmacological Research. 2021;163:105207. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/
Patel Y, Chawla J, Parmar MS. "Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?" Current Oncology Reports. 2025;27(9):1070-1079. https://pubmed.ncbi.nlm.nih.gov/40715995/
Benjamin DJ, et al. "Ivermectin in cancer, 2025: Internet trends, scientific data, ongoing trials, and news coverage." Annals of Oncology. 2025;36(Suppl). https://www.annalsofoncology.org/article/S0923-7534(25)04365-0/fulltext
ClinicalTrials.gov. Study NCT05318469: Ivermectin in Combination With Balstilimab in Metastatic Triple-Negative Breast Cancer. https://clinicaltrials.gov/study/NCT05318469
National Cancer Institute. "Clinical Trials Information for Patients and Caregivers." https://www.cancer.gov/about-cancer/treatment/clinical-trials
Kaur B, Blavo C, Parmar MS. "Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy." Cureus. 2024;16(3):e56025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11008553/
